JP2024521329A5 - - Google Patents

Info

Publication number
JP2024521329A5
JP2024521329A5 JP2023573384A JP2023573384A JP2024521329A5 JP 2024521329 A5 JP2024521329 A5 JP 2024521329A5 JP 2023573384 A JP2023573384 A JP 2023573384A JP 2023573384 A JP2023573384 A JP 2023573384A JP 2024521329 A5 JP2024521329 A5 JP 2024521329A5
Authority
JP
Japan
Prior art keywords
approximately
seq
range
buffering agent
mtorr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521329A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/031694 external-priority patent/WO2022256359A1/en
Publication of JP2024521329A publication Critical patent/JP2024521329A/ja
Publication of JP2024521329A5 publication Critical patent/JP2024521329A5/ja
Pending legal-status Critical Current

Links

JP2023573384A 2021-06-01 2022-06-01 凍結乾燥タンパク質製剤を製造する迅速な方法 Pending JP2024521329A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163195265P 2021-06-01 2021-06-01
US63/195,265 2021-06-01
PCT/US2022/031694 WO2022256359A1 (en) 2021-06-01 2022-06-01 Accelerated method of making lyophilized protein formualtions

Publications (2)

Publication Number Publication Date
JP2024521329A JP2024521329A (ja) 2024-05-31
JP2024521329A5 true JP2024521329A5 (enExample) 2025-06-09

Family

ID=82100125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573384A Pending JP2024521329A (ja) 2021-06-01 2022-06-01 凍結乾燥タンパク質製剤を製造する迅速な方法

Country Status (14)

Country Link
US (1) US20240368254A1 (enExample)
EP (1) EP4346778A1 (enExample)
JP (1) JP2024521329A (enExample)
KR (1) KR20240016260A (enExample)
CN (1) CN117241787A (enExample)
AR (1) AR126044A1 (enExample)
AU (1) AU2022285665A1 (enExample)
BR (1) BR112023024757A2 (enExample)
CA (1) CA3217210A1 (enExample)
CL (1) CL2023003443A1 (enExample)
IL (1) IL307677A (enExample)
MX (1) MX2023014034A (enExample)
TW (1) TW202313108A (enExample)
WO (1) WO2022256359A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4553432B1 (en) 2023-11-08 2026-04-29 Bachem Holding AG Drying bag and drying system
WO2025099273A1 (en) 2023-11-08 2025-05-15 Bachem Holding Ag Drying bag and drying system

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
CA2409991A1 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
KR20100052545A (ko) 2007-08-28 2010-05-19 바이오겐 아이덱 엠에이 인코포레이티드 Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물
EA202090731A1 (ru) * 2017-09-15 2020-06-11 Эмджен Инк. Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка
EP4200333A1 (en) * 2020-08-24 2023-06-28 Amgen Inc. Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine
JP2023541133A (ja) * 2020-09-14 2023-09-28 アムジエン・インコーポレーテツド 凍結乾燥タンパク質製剤を作製する方法

Similar Documents

Publication Publication Date Title
JP2024521329A5 (enExample)
US10286037B2 (en) Methods of producing lyophilized polypeptide composition formulations comprising volatile additives
RU2607526C2 (ru) Липопептидные композиции и родственные способы
US8795686B2 (en) Stable, dried rotavirus vaccine, compositions and process for preparation thereof
US12449198B2 (en) Target residual moisture content for lyophilized drug product
US12251474B2 (en) Process for lyophilized pharmaceutical formulations of a therapeutic protein
EP2458990A1 (en) Methods for producing high concentration lyophilized pharmaceutical formulations
EP0065905A1 (fr) Perfectionnements apportés aux agents de stabilisation de virus vivants pour la préparation de vaccins, et vaccins stabilisés contenant lesdits agents de stabilisation
JP2021521119A5 (enExample)
JP2023538669A5 (enExample)
WO2011042663A1 (fr) Excipient stabilisant pour vaccin a virus entiers inactives
JP3105494B2 (ja) 蛋白質を安定化するための改良された方法
WO2011066291A4 (en) Lyophilization methods, compositions, and kits
US20050226893A1 (en) Lyophilization method to improve excipient crystallization
US20090208509A1 (en) Pharmaceutical formulation of an antibody against IL-1R
RU2014151424A (ru) Термостабильные составы вакцины
US20210338586A1 (en) Stable lyophilized dosage form of protein
JP7085482B2 (ja) スタフィロコッカス感染症のための凍結乾燥製剤を製造する方法
CN120789003A (zh) 一种蛋白冻干制剂与高浓度蛋白制剂的制备方法
JP2023524444A5 (enExample)
JP2024523443A5 (enExample)
JP2025016453A5 (enExample)
JP2023501155A5 (enExample)
IL307150A (en) Modified coronavirus spike proteins to improve titers
HK40033832A (en) Process for lyophilized pharmaceutical formulation of a therapeutic protein